Lignan contents of Schisandra chinensis (Turcz.) Baill. from different origins-A new model for evaluating the content of prominent components of Chinese herbs.

Publisher: Urban & Fischer Verlag Country of Publication: Germany NLM ID: 9438794 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1618-095X (Electronic) Linking ISSN: 09447113 NLM ISO Abbreviation: Phytomedicine Subsets: MEDLINE

Publication: Stuttgart : Urban & Fischer Verlag
Original Publication: Stuttgart ; New York : G. Fischer, c1994-

Schisandra*/chemistry ; Lignans*/analysis ; Drugs, Chinese Herbal*/chemistry ; Drugs, Chinese Herbal*/analysis ; Cyclooctanes*/analysis; Chromatography, High Pressure Liquid/methods ; China ; Polycyclic Compounds/analysis ; Dioxoles/analysis ; Quality Control ; Principal Component Analysis

Background: As a traditional Chinese herbal medicine, Schisandra chinensis exhibits various effects such as liver protection, blood sugar regulation, blood lipid regulation, immune function regulation, antidepressant activity, etc. However, because of its intricate composition, diverse origins, and medicinal effects depending on complex compound groups, there are differences in the lignan composition of S. chinensis from different origins. Therefore, it is currently difficult to evaluate the quality of medicinal materials from plants of different origins using a single qualitative quality control index.
Purpose: This paper aims to investigate the potential relationship between the lignan components of S. chinensis from different origins and to establish stable assessment indices for determining the lignan content of S. chinensis from multiple perspectives.
Methods: In this study, we collected S. chinensis samples of seven major origins in China, and randomly sampled 6-9 batches of each origin for a total of 60 batches. The lignan content was determined by HPLC, and its distribution law of the ratio of each lignan component of S. chinensis to Schisandrol A content was analyzed. Combining network pharmacology and differential analysis between samples, the stable and effective substances used as quality markers were determined.
Results: There were some correlations among the lignan contents of S. chinensis, some correlations between schisandrin A and other lignans of S. chinensis could be determined. The ratio of each component to the indicator component schisandrol A was evenly distributed and reflected the lignan content of S. chinensis to some extent. Four substances (schisandrol A, schisandrol B, schisantherin A, and schisandrin C) were determined by network pharmacology combined with the analysis results of HCA, PCA and PLS-DA to further optimize the model. They displayed a strong connection with the core target, a large contribution rate to the principal components, and a stable content in each batch of samples, suggesting that these components may be the main active substances of S. chinensis lignans. Therefore, they could be used as main indicators evaluating the advantages and disadvantages of S. chinensis by examining the consistency of component proportions.
Conclusion: This method can intuitively evaluate the content of main lignans in S. chinensis. This quality assessment model is an exploration of the multi-component comprehensive evaluation system of S. chinensis, providing a new concept for the quality evaluation system of Chinese herbal medicines.
Competing Interests: Declaration of competing interest The authors declare that there is no conflict of interest.
(Copyright © 2024 Elsevier GmbH. All rights reserved.)

Keywords: Component variability; Network pharmacology; Quality evaluation; Ratio consistency; Schisandra chinensis

0 (Lignans)
0 (Drugs, Chinese Herbal)
0 (Cyclooctanes)
74XQL5DO3S (schizandrin A)
0 (Polycyclic Compounds)
0 (schisandrol A)
0 (Dioxoles)
C8754W6B3G (schizandrin C)
58546-54-6 (schizandrol B)
82042-38-4 (schizandrer A)

Date Created: 20240329 Date Completed: 20240430 Latest Revision: 20240430

20240430

10.1016/j.phymed.2024.155361

38552434